Accepted Articles
Back to the articles list |
Back to browse issues page
1- Department of Medical Genetics, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Abstract:
Aim: Neurodevelopmental disorders(NDD) are clinically and genetically heterogeneous group of diseases. It is difficult to diagnose the underlying origin of these diseases. We aim to evaluate whole exome sequencing(WES) results in our NDD patients and the responsible genetic variants.
Methods: In the study, WES analysis results of 25 NDD patients were evaluated retrospectively and the diagnostic yield of WES in our cases and clinical findings were examined.
Results: With WES analysis, we diagnosed 13(52%) of the patients with pathogenic(P) and likely pathogenic(LP) variants and 12(48%) patients remained unclear with variants of unsignificance(VUS). However, with phenotype consistence and following segregation analysis, we also evaluated 2 VUS as the disease causing variants and our yield rate increased to 60%. We also reported the secondary findings.
Conclusion: The diagnostic yield of WES in NDD was 60% in our study. The latest ACMG guideline recommends WES as the first-tier test in NDD. WES is time and cost effective when performed in well-selected patient, plus determining the underlying cause of NDD will provide more accurate diagnosis and clinical follow-up for the patients.
Methods: In the study, WES analysis results of 25 NDD patients were evaluated retrospectively and the diagnostic yield of WES in our cases and clinical findings were examined.
Results: With WES analysis, we diagnosed 13(52%) of the patients with pathogenic(P) and likely pathogenic(LP) variants and 12(48%) patients remained unclear with variants of unsignificance(VUS). However, with phenotype consistence and following segregation analysis, we also evaluated 2 VUS as the disease causing variants and our yield rate increased to 60%. We also reported the secondary findings.
Conclusion: The diagnostic yield of WES in NDD was 60% in our study. The latest ACMG guideline recommends WES as the first-tier test in NDD. WES is time and cost effective when performed in well-selected patient, plus determining the underlying cause of NDD will provide more accurate diagnosis and clinical follow-up for the patients.
Keywords: Neurodevelopmental disorder, Whole exome sequencing, Developmental delay disorders, Intellectual disabilities, Congenital abnormalities
Type of Study: Original |
Subject:
Cellular and molecular Neuroscience
Received: 2023/02/1 | Accepted: 2024/02/10
Received: 2023/02/1 | Accepted: 2024/02/10
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
